DryShips Inc. (DRYS) to pay $0.02 on Mar 8, 2018; Calithera Biosciences, Inc. (CALA) Had 4 Bullish Analysts

February 15, 2018 - By Marie Mckinney

Among 5 analysts covering Calithera Biosciences (NASDAQ:CALA), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Calithera Biosciences had 9 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Calithera Biosciences, Inc. (NASDAQ:CALA) earned “Buy” rating by H.C. Wainwright on Monday, June 12. The stock of Calithera Biosciences, Inc. (NASDAQ:CALA) has “Buy” rating given on Thursday, January 5 by H.C. Wainwright. The rating was initiated by Citigroup on Friday, July 24 with “Buy”. On Tuesday, March 28 the stock rating was maintained by H.C. Wainwright with “Buy”. On Tuesday, January 24 the stock rating was upgraded by Citigroup to “Neutral”. The rating was maintained by JMP Securities on Wednesday, March 9 with “Market Outperform”. The firm has “Sell” rating given on Tuesday, October 25 by Citigroup. See Calithera Biosciences, Inc. (NASDAQ:CALA) latest ratings:

05/10/2017 Broker: William Blair Rating: Outperform Initiates Coverage On

DryShips Inc. (NASDAQ:DRYS) is expected to pay $0.02 on Mar 8, 2018. $0.10 is the ADY. (NASDAQ:DRYS) shareholders before Feb 16, 2018 will receive the $0.02 dividend. DryShips Inc.’s current price of $3.74 translates into 0.64% yield. DryShips Inc.’s dividend has Feb 20, 2018 as record date. Feb 6, 2018 is the announcement. The stock decreased 0.27% or $0.01 during the last trading session, reaching $3.74. About 1.52 million shares traded. DryShips Inc. (NASDAQ:DRYS) has declined 99.99% since February 15, 2017 and is downtrending. It has underperformed by 116.69% the S&P500.

DryShips Inc. owns and operates ocean going cargo vessels worldwide. The company has market cap of $389.99 million. It operates through two divisions, Drybulk and Offshore Support. It currently has negative earnings. The Drybulk segment offers drybulk commodities transportation services for the steel, electric utility, construction, and agri-food industries.

The stock increased 0.35% or $0.03 during the last trading session, reaching $7.1. About 567,693 shares traded. Calithera Biosciences, Inc. (NASDAQ:CALA) has risen 278.82% since February 15, 2017 and is uptrending. It has outperformed by 262.12% the S&P500.

Investors sentiment decreased to 1.22 in Q3 2017. Its down 2.03, from 3.25 in 2017Q2. It dived, as 16 investors sold Calithera Biosciences, Inc. shares while 21 reduced holdings. 14 funds opened positions while 31 raised stakes. 25.24 million shares or 49.47% less from 49.95 million shares in 2017Q2 were reported. Atika Cap Mngmt Limited Liability Corp holds 1.06% or 234,603 shares. Bancshares Of America De has invested 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). Goldman Sachs Grp Inc has 138,491 shares. Clarivest Asset Mngmt Limited Com invested in 0.02% or 49,474 shares. Citigroup Inc invested 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). Deutsche Financial Bank Ag, Germany-based fund reported 167,467 shares. Credit Suisse Ag reported 31,371 shares. Gsa Capital Ltd Liability Partnership holds 30,257 shares or 0.03% of its portfolio. Dupont Capital owns 16,394 shares. Pnc Fincl Svcs Gru Inc reported 1,000 shares. Voya Inv Management Limited Liability holds 0% in Calithera Biosciences, Inc. (NASDAQ:CALA) or 14,186 shares. Fred Alger Mngmt Inc holds 10,000 shares or 0% of its portfolio. Pacad Invest accumulated 10,000 shares or 0.03% of the stock. Jacobs Levy Equity Mgmt owns 18,565 shares. Amer Group Inc reported 20,536 shares or 0% of all its holdings.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>